A Phase I trial of voruciclib +/- venetoclax for the treatment of NHL and AML

A Phase I trial of voruciclib +/- venetoclax for the treatment of NHL and AML

01:29 |

Related Videos

VJHemOnc: expert-led coverage of hematological malignancies

VJHemOnc: expert-led coverage of hematological malignancies

The stages and treatments for myelodysplastic syndromes

The stages and treatments for myelodysplastic syndromes

The efficacy of CAR T-cell therapy in Richter’s transformation

The efficacy of CAR T-cell therapy in Richter’s transformation

The potential of immunotherapies in the myeloma treatment landscape

The potential of immunotherapies in the myeloma treatment landscape

Managing adverse events associated with BTKis when treating patients with MCL

Managing adverse events associated with BTKis when treating patients with MCL

Zanubrutinib in patients with B-cell malignancies who are acalabrutinib-intolerant

Zanubrutinib in patients with B-cell malignancies who are acalabrutinib-intolerant

The potential of daratumumab in HR-SMM: single agent and Dara-RVd

The potential of daratumumab in HR-SMM: single agent and Dara-RVd

Getting involved in real-world studies for CLL through ERIC

Getting involved in real-world studies for CLL through ERIC

The ethnic diversity in the presentation and outcome of WM and MGUS in the United Kingdom

The ethnic diversity in the presentation and outcome of WM and MGUS in the United Kingdom

Splicing mutations in post-ET/post-PV myelofibrosis

Splicing mutations in post-ET/post-PV myelofibrosis

Genomic profiling SMM

Genomic profiling SMM

Unmet needs in AML: TP53 mutations and maintenance therapy

Unmet needs in AML: TP53 mutations and maintenance therapy

Frontline treatment for CLL: the changing paradigm

Frontline treatment for CLL: the changing paradigm

The treatment of AML within the United Kingdom NHS framework

The treatment of AML within the United Kingdom NHS framework

The real-world efficacy of CAR-T cells in post-transplant relapsed B-ALL

The real-world efficacy of CAR-T cells in post-transplant relapsed B-ALL

Triplet vs quadruplet regimens for NDMM: selecting between these options

Triplet vs quadruplet regimens for NDMM: selecting between these options

Mitigating cardiological toxicities associated with BTKi in B-cell malignancies

Mitigating cardiological toxicities associated with BTKi in B-cell malignancies

Challenges in the treatment and management of ET and the need to improve therapeutic approaches

Challenges in the treatment and management of ET and the need to improve therapeutic approaches

Challenges in developing immunotherapies for CLL compared to other hematologic malignancies

Challenges in developing immunotherapies for CLL compared to other hematologic malignancies

Advice for physicians when managing bispecific antibody treatment for patients with myeloma

Advice for physicians when managing bispecific antibody treatment for patients with myeloma

© 2024 Tubidy